



ASKA PHARMACEUTICAL AND TESORX PHARMA EXPAND TERRITORY AND SCOPE OF PARTNERING AGREEMENT FOR TESORX'S ORAL TESTOSTERONE PRODUCT

(TOKYO, JAPAN & SAN FRANCISCO, CA.) December 1, 2017 -- ASKA Pharmaceutical Co., Ltd. and TesoRx Pharma LLC announced today we have expanded our existing collaboration to develop and commercialize TesoRx's novel oral testosterone product, TSX-011, in Japan to include South East Asia. In addition, the parties have agreed to include exclusive rights to TesoRx's oral testosterone for the treatment of constitutional delay in growth and puberty ("CDGP") for Japan and South East Asia. ASKA has simultaneously made an equity investment in TesoRx.

For further information visit <http://www.tesorx.com/december-1-2017>